Brief: Oasmia Presents Cantrixil Final Phase I Data At The 2021 AACR Annual Meeting

Vivesto AB

12/04/2021 06:03

April 12 (Reuters) - Oasmia Pharmaceutical AB  OASM.ST :
    * OASMIA PRESENTS CANTRIXIL FINAL PHASE I DATA AT THE 2021
AACR
ANNUAL MEETING
    * DATA SET ILLUSTRATES POTENTIAL OF INVESTIGATIONAL DRUG
CANDIDATE
CANTRIXIL AS A TREATMENT FOR OVARIAN CANCER
    * FURTHER CLINICAL EVALUATION OF DATA HAS CONFIRMED THAT
CANTRIXIL
MAY INDUCE OVARIAN CANCER STEM CELL (OCSC) DEATH AND SENSITIZE
CANCER CELLS TO STANDARD CHEMOTHERAPY
    * AN ENCOURAGING SIGNAL WAS ALSO SEEN IN PATIENTS WITH
PLATINUM-REFRACTORY OVARIAN CANCER
    * FULL DATA CONFIRMS MAXIMUM TOLERATED DOSE OF CANTRIXIL TO
BE 5.0
MG/KG WHEN ADMINISTERED WEEKLY VIA INTRAPERITONEAL INJECTION

Source text for Eikon:  ID:nMFN6z7MVB 
Further company coverage:  OASM.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))